Nivolumab + ipilimumab (RCC, 1L IMDC intermediate/poor)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-NIVOLUMAB` `DRUG-IPILIMUMAB`

ID	`REG-NIVO-IPI-RCC`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-RCC-2024` `SRC-NCCN-KIDNEY-2025`

Notes

CheckMate-214 IMDC intermediate/poor. Nivo q4w maintenance up to 2 years.

Used By

Indication

IND-RCC-METASTATIC-1L-NIVO-IPI - IND-RCC-METASTATIC-1L-NIVO-IPI

Regimen

REG-IPI-NIVO-ESOPH-SCC - Nivolumab + ipilimumab (ESCC, 1L metastatic; CheckMate-648)